Intraperitoneal administration of adeno-associated virus encoding microRNA-29b for the treatment of peritoneal metastasis.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
19
03
2024
accepted:
19
09
2024
revised:
07
09
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
aheadofprint
Résumé
This study explores a novel therapeutic approach for peritoneal metastasis (PM) using AAV-mediated delivery of tumor suppressor microRNA-29b (miR-29b) to peritoneal mesothelial cells (PMC). AAV serotypes 2 and DJ demonstrate high transduction efficiency for human and murine PMC, respectively. In vitro analysis indicates that AAV vectors encoding miR-29b precursor successfully elevate miR-29b expression in PMC and their secreted small extracellular vesicle (sEV), thereby inhibiting mesothelial mesenchymal transition and reducing subsequent attachment of tumor cells. A single intraperitoneal (IP) administration of AAV-DJ-miR-29b demonstrates robust and sustained transgene expression, suppressing peritoneal fibrosis and inhibiting the development of PM from gastric and pancreatic cancers. Additionally, AAV-DJ-miR-29b enhances the efficacy of IP chemotherapy using paclitaxel, restraining the growth of established PM. While conventional gene therapy for cancer encounters challenges targeting tumor cells directly but delivering miRNA to the tumor stroma offers a straightforward and efficient means of altering the microenvironment, leading to substantial inhibition of tumor growth. AAV-mediated miR-29b delivery to peritoneum via IP route presents a simple, minimally invasive, and promising therapeutic strategy for refractory PM.
Identifiants
pubmed: 39390194
doi: 10.1038/s41417-024-00837-w
pii: 10.1038/s41417-024-00837-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 20K07704
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 23K06772
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP23ama221224
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al. Ovarian cancer. Crit Rev Oncol Hematol. 2006;60:159–79.
pubmed: 17018256
doi: 10.1016/j.critrevonc.2006.03.004
Sugarbaker PH. Peritoneal metastases from gastrointestinal cancer. Curr Oncol Rep. 2018;20:62.
pubmed: 29884974
doi: 10.1007/s11912-018-0703-0
Koemans WJ, Lurvink RJ, Grootscholten C, Verhoeven RHA, de Hingh IH, van Sandick JW. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021;24:800–9.
pubmed: 33495964
doi: 10.1007/s10120-021-01160-1
Lurvink RJ, Bakkers C, Rijken A, van Erning FN, Nienhuijs SW, Burger JW, et al. Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: a nationwide study. Eur J Surg Oncol. 2021;47:1026–33.
pubmed: 33272737
doi: 10.1016/j.ejso.2020.11.135
Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53–63.
pubmed: 8849943
doi: 10.1007/978-1-4613-1247-5_4
Steuperaert M, Debbaut C, Segers P, Ceelen W. Modelling drug transport during intraperitoneal chemotherapy. Pleura Peritoneum. 2017;2:73–83.
pubmed: 30911635
pmcid: 6405034
doi: 10.1515/pp-2017-0004
Tentes AA, Pallas N, Karamveri C, Kyziridis D, Hristakis C. Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer. J Buon. 2018;23:482–7.
pubmed: 29745096
Brandl A, Yonemura Y, Glehen O, Sugarbaker P, Rau B. Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI. Eur J Surg Oncol. 2021;47:172–80.
pubmed: 33071173
doi: 10.1016/j.ejso.2020.10.006
Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922–9.
pubmed: 29746229
doi: 10.1200/JCO.2018.77.8613
Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, et al. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Br J Surg. 2020;107:1811–7.
pubmed: 32638367
doi: 10.1002/bjs.11792
Mutsaers SE. The mesothelial cell. Int J Biochem Cell Biol. 2004;36:9–16.
pubmed: 14592528
doi: 10.1016/S1357-2725(03)00242-5
Gordillo CH, Sandoval P, Muñoz-Hernández P, Pascual-Antón L, López-Cabrera M, Jiménez-Heffernan JA. Mesothelial-to-mesenchymal transition contributes to the generation of carcinoma-associated fibroblasts in locally advanced primary colorectal carcinomas. Cancers (Basel). 2020;12:499.
pubmed: 32098058
doi: 10.3390/cancers12020499
Ohzawa H, Saito A, Kumagai Y, Kimura Y, Yamaguchi H, Hosoya Y, et al. Reduced expression of exosomal miR‑29s in peritoneal fluid is a useful predictor of peritoneal recurrence after curative resection of gastric cancer with serosal involvement. Oncol Rep. 2020;43:1081–8.
pubmed: 32323853
pmcid: 7057811
Ohzawa H, Kumagai Y, Yamaguchi H, Miyato H, Sakuma Y, Horie H, et al. Exosomal microRNA in peritoneal fluid as a biomarker of peritoneal metastases from gastric cancer. Ann Gastroenterol Surg. 2020;4:84–93.
pubmed: 32021962
doi: 10.1002/ags3.12296
Yan B, Guo Q, Fu FJ, Wang Z, Yin Z, Wei YB, et al. The role of miR-29b in cancer: regulation, function, and signaling. Onco Targets Ther. 2015;8:539–48.
pubmed: 25767398
pmcid: 4354468
Kwon JJ, Factora TD, Dey S, Kota J. A systematic review of miR-29 in cancer. Mol Ther Oncolytics. 2019;12:173–94.
pubmed: 30788428
doi: 10.1016/j.omto.2018.12.011
Alizadeh M, Safarzadeh A, Beyranvand F, Ahmadpour F, Hajiasgharzadeh K, Baghbanzadeh A, et al. The potential role of miR-29 in health and cancer diagnosis, prognosis, and therapy. J Cell Physiol. 2019;234:19280–97.
pubmed: 30950056
doi: 10.1002/jcp.28607
de Abreu RC, Ramos CV, Becher C, Lino M, Jesus C, da Costa Martins PA, et al. Exogenous loading of miRNAs into small extracellular vesicles. J Extracell Vesicles. 2021;10:e12111.
pubmed: 34377372
pmcid: 8329988
doi: 10.1002/jev2.12111
Kimura Y, Ohzawa H, Miyato H, Kaneko Y, Kuchimaru T, Takahashi R, et al. Intraperitoneal transfer of microRNA-29b-containing small extracellular vesicles can suppress peritoneal metastases of gastric cancer. Cancer Sci. 2023;114:2939–50.
pubmed: 36939028
pmcid: 10323101
doi: 10.1111/cas.15793
Kimura Y, Ohzawa H, Miyato H, Kaneko Y, Saito A, Takahashi K, et al. MiR-29b may suppresses peritoneal metastases through inhibition of the mesothelial-mesenchymal transition (MMT) of human peritoneal mesothelial cells. Sci Rep. 2022;12:205.
pubmed: 34997082
pmcid: 8742040
doi: 10.1038/s41598-021-04065-2
Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15:445–51.
pubmed: 24840552
pmcid: 4393649
doi: 10.1038/nrg3742
Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021;178:113834.
pubmed: 34492233
doi: 10.1016/j.addr.2021.113834
Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31:317–34.
pubmed: 28669112
pmcid: 5548848
doi: 10.1007/s40259-017-0234-5
Yamamoto M, Nomura S, Hosoi A, Nagaoka K, Iino T, Yasuda T, et al. Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth. Cancer Sci. 2018;109:1480–92.
pubmed: 29532565
pmcid: 5980194
doi: 10.1111/cas.13569
Kumagai Y, Futoh Y, Miyato H, Ohzawa H, Yamaguchi H, Saito S, et al. Effect of systemic or intraperitoneal administration of anti-PD-1 antibody for peritoneal metastases from gastric cancer. Vivo. 2022;36:1126–35.
doi: 10.21873/invivo.12811
Zimmerman RJ, Chan A, Leadon SA. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res. 1989;49:1644–8.
pubmed: 2924312
Riera M, McCulloch P, Pazmany L, Jagoe T. Optimal method for isolation of human peritoneal mesothelial cells from clinical samples of omentum. J Tissue Viability. 2006;16:22–4.
pubmed: 17153120
doi: 10.1016/S0965-206X(06)64005-9
Mizukami H, Mimuro J, Ogura T, Okada T, Urabe M, Kume A, et al. Adipose tissue as a novel target for in vivo gene transfer by adeno-associated viral vectors. Hum Gene Ther. 2006;17:921–8.
pubmed: 16972760
doi: 10.1089/hum.2006.17.921
Watano R, Ohmori T, Hishikawa S, Sakata A, Mizukami H. Utility of microminipigs for evaluating liver-mediated gene expression in the presence of neutralizing antibody against vector capsid. Gene Ther. 2020;27:427–34.
pubmed: 32066928
pmcid: 7500982
doi: 10.1038/s41434-020-0125-0
Yoshiba T, Saga Y, Urabe M, Uchibori R, Matsubara S, Fujiwara H, et al. CRISPR/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6. Oncol Lett. 2019;17:2197–206.
pubmed: 30675284
Kurosaki F, Uchibori R, Mato N, Sehara Y, Saga Y, Urabe M, et al. Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract. Gene Ther. 2017;24:290–7.
pubmed: 28346434
doi: 10.1038/gt.2017.19
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18:e3000410.
pubmed: 32663219
pmcid: 7360023
doi: 10.1371/journal.pbio.3000410
Horita M, Farquharson C, Stephen LA. The role of miR-29 family in disease. J Cell Biochem. 2021;122:696–715.
pubmed: 33529442
pmcid: 8603934
doi: 10.1002/jcb.29896
Dalgaard LT, Sørensen AE, Hardikar AA, Joglekar MV. The microRNA-29 family: role in metabolism and metabolic disease. Am J Physiol Cell Physiol. 2022;323:C367–c377.
pubmed: 35704699
doi: 10.1152/ajpcell.00051.2022
Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32:466–77.
pubmed: 33548389
doi: 10.1016/j.annonc.2021.01.074
Ogura T, Mizukami H, Mimuro J, Madoiwa S, Okada T, Matsushita T, et al. Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer. J Gene Med. 2006;8:990–7.
pubmed: 16685745
doi: 10.1002/jgm.916
Isayeva T, Ren C, Ponnazhagan S. Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway. Gene Ther. 2007;14:138–46.
pubmed: 16943851
doi: 10.1038/sj.gt.3302853
Ohzawa H, Kimura Y, Saito A, Yamaguchi H, Miyato H, Sakuma Y, et al. Ratios of miRNAs in peritoneal exosomes are useful biomarkers to predict tumor response to intraperitoneal chemotherapy in patients with peritoneal metastases from gastric cancer. Ann Surg Oncol. 2020;27:5057–64.
pubmed: 32804324
doi: 10.1245/s10434-020-09007-2
Liu JF, Lee CW, Tsai MH, Tang CH, Chen PC, Lin LW, et al. Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells. Biochem Pharm. 2018;155:537–46.
pubmed: 30031810
doi: 10.1016/j.bcp.2018.07.024
Zhang S, Yang H, Xiang X, Liu L, Huang H, Tang G. THBS2 is closely related to the poor prognosis and immune cell infiltration of gastric cancer. Front Genet. 2022;13:803460.
pubmed: 35186032
pmcid: 8853287
doi: 10.3389/fgene.2022.803460
Ranade SS, Woo SH, Dubin AE, Moshourab RA, Wetzel C, Petrus M, et al. Piezo2 is the major transducer of mechanical forces for touch sensation in mice. Nature. 2014;516:121–5.
pubmed: 25471886
pmcid: 4380172
doi: 10.1038/nature13980
Katsuta E, Takabe K, Vujcic M, Gottlieb PA, Dai T, Mercado-Perez A. et al. Mechano-sensing channel PIEZO2 enhances invasive phenotype in triple-negative breast cancer. Int J Mol Sci. 2022;23:9909.
pubmed: 36077309
pmcid: 9455988
doi: 10.3390/ijms23179909
Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009;69:6275–81.
pubmed: 19584290
pmcid: 2719680
doi: 10.1158/0008-5472.CAN-08-4517
Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2:269–74.
pubmed: 11224528
doi: 10.1038/85339
Vigdorovich V, Ramagopal UA, Lázár-Molnár E, Sylvestre E, Lee JS, Hofmeyer KA, et al. Structure and T cell inhibition properties of B7 family member, B7-H3. Structure. 2013;21:707–17.
pubmed: 23583036
pmcid: 3998375
doi: 10.1016/j.str.2013.03.003
Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. 2021;27:1227–35.
pubmed: 33051306
doi: 10.1158/1078-0432.CCR-20-2584
Getu AA, Tigabu A, Zhou M, Lu J, Fodstad Ø, Tan M. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22:43.
pubmed: 36859240
pmcid: 9979440
doi: 10.1186/s12943-023-01751-9
Calabrò L, Sigalotti L, Fonsatti E, Bertocci E, Di Giacomo AM, Danielli R, et al. Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications. J Cell Physiol. 2011;226:2595–600.
pubmed: 21792917
doi: 10.1002/jcp.22600
Gu W, Li G, Zhang W, Zhang X, He Y, Huang L, et al. MiR-29b regulates Th2 cell differentiation in asthma by targeting inducible B7-H3 and STAT3. Clin Transl Allergy. 2022;12:e12114.
pubmed: 35079347
pmcid: 8764737
doi: 10.1002/clt2.12114
Heo YA. Etranacogene dezaparvovec: first approval. Drugs. 2023;83:347–52.
pubmed: 36802324
doi: 10.1007/s40265-023-01845-0
Hu ML, Edwards TL, O’Hare F, Hickey DG, Wang JH, Liu Z, et al. Gene therapy for inherited retinal diseases: progress and possibilities. Clin Exp Optom. 2021;104:444–54.
pubmed: 33689657
doi: 10.1080/08164622.2021.1880863
Hudry E, Vandenberghe LH. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 2019;101:839–62.
pubmed: 30844402
doi: 10.1016/j.neuron.2019.02.017
Brandon-Warner E, Benbow JH, Swet JH, Feilen NA, Culberson CR, McKillop IH, et al. Adeno-associated virus serotype 2 vector-mediated reintroduction of microRNA-19b attenuates hepatic fibrosis. Hum Gene Ther. 2018;29:674–86.
pubmed: 29281894
pmcid: 6004090
doi: 10.1089/hum.2017.035
Heller KN, Mendell JT, Mendell JR, Rodino-Klapac LR. MicroRNA-29 overexpression by adeno-associated virus suppresses fibrosis and restores muscle function in combination with micro-dystrophin. JCI Insight. 2017;2:e93309.
pubmed: 28469083
pmcid: 5414552
doi: 10.1172/jci.insight.93309
Stoica L, Todeasa SH, Cabrera GT, Salameh JS, ElMallah MK, Mueller C, et al. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol. 2016;79:687–700.
pubmed: 26891182
pmcid: 5374859
doi: 10.1002/ana.24618
Wu YF, Mao WF, Zhou YL, Wang XT, Liu PY, Tang JB. Adeno-associated virus-2-mediated TGF-β1 microRNA transfection inhibits adhesion formation after digital flexor tendon injury. Gene Ther. 2016;23:167–75.
pubmed: 26381218
doi: 10.1038/gt.2015.97
Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137:1005–17.
pubmed: 19524505
pmcid: 2722880
doi: 10.1016/j.cell.2009.04.021